UCA1 and prostate cancer: Interestingly, besides its involvement in BC drug resistance, lncRNA UCA1 was shown to promote chemoresistance against various agents in different cancers, such as prostate cancer (docetaxel) [266], ovarian cancer (cisplatin) [263], colorectal cancer (5-FU) [267], chronic myeloid leukemia (imatinib) [268], bladder cancer (cisplatin, gemcitabine) [269], and gastric cancer (MDR) [270].